drugset
drugset / Trial / NCT03568331

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

NCT03568331 ↗

Phase 3 Completed 375 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.

Timeline

Start
2018-07-09
Primary completion
2019-12-27
Completion
2019-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Tradipitant Small molecule — Oral

Indications

atopic eczema